Novartis Income Statement Research

NVS Stock

USD 94.36 1.79 1.93%

Most accounts from Novartis' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Novartis Valuation and Novartis Correlation analysis.

At this time, Novartis' Net Income From Continuing Ops is comparatively stable compared to the past year. Tax Provision is likely to gain to about 1.7 B in 2024, whereas Interest Expense is likely to drop slightly above 550.6 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	37.0B	36.3B	34.2B	32.3B
Total Revenue	52.9B	51.8B	46.7B	46.2B

Gross Profit Total Revenue

Novartis income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Minority Interest	Discontinued Operations	Net Income From Continuing Ops	Tax Provision	Interest Income	Extraordinary Items	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.93	0.55	0.71	0.58	0.64	0.59	0.19	0.24	0.88	0.52	0.4	0.69	0.19	0.02	0.31	-0.02	-0.07	0.3	-0.05	0.34	0.04	-0.51	-0.04	0.43
Interest Expense	0.93		0.49	0.8	0.78	0.81	0.79	0.29	0.4	0.9	0.63	0.63	0.85	0.35	0.19	0.32	0.16	0.15	0.14	0.08	0.34	0.09	-0.44	-0.16	0.21
Selling General Administrative	0.55	0.49		0.23	0.04	0.17	0.03	0.28	0.35	0.32	0.48	-0.2	0.2	0.36	0.03	0.29	-0.04	-0.53	0.41	0.32	0.7	0.25	-0.54	-0.02	0.56
Selling And Marketing Expenses	0.71	0.8	0.23		0.89	0.93	0.86	0.29	0.31	0.91	0.49	0.7	0.93	0.26	-0.02	0.26	-0.02	0.32	0.03	0.02	0.09	0.01	-0.09	0.11	0.26
Total Revenue	0.58	0.78	0.04	0.89		0.98	0.99	0.35	0.42	0.83	0.54	0.93	0.98	0.37	0.13	0.28	0.23	0.52	-0.07	0.11	-0.01	0.09	0.02	-0.14	-0.11
Gross Profit	0.64	0.81	0.17	0.93	0.98		0.95	0.42	0.45	0.88	0.59	0.83	0.98	0.4	0.02	0.32	0.23	0.41	0.01	0.14	0.1	0.14	0.02	-0.11	0.01
Other Operating Expenses	0.59	0.79	0.03	0.86	0.99	0.95		0.27	0.36	0.82	0.49	0.95	0.97	0.3	0.2	0.23	0.19	0.54	-0.08	0.04	-0.05	0.02	-0.04	-0.11	-0.12
Operating Income	0.19	0.29	0.28	0.29	0.35	0.42	0.27		0.94	0.32	0.88	0.2	0.3	0.94	-0.26	0.76	0.51	-0.19	0.15	0.89	0.57	0.95	0.01	-0.47	-0.11
Ebit	0.24	0.4	0.35	0.31	0.42	0.45	0.36	0.94		0.34	0.95	0.31	0.37	1.0	0.08	0.78	0.45	-0.13	0.01	0.94	0.51	0.89	-0.13	-0.46	-0.07
Research Development	0.88	0.9	0.32	0.91	0.83	0.88	0.82	0.32	0.34		0.57	0.65	0.89	0.28	-0.04	0.38	-0.01	0.14	0.2	0.01	0.16	0.08	-0.23	0.07	0.32
Ebitda	0.52	0.63	0.48	0.49	0.54	0.59	0.49	0.88	0.95	0.57		0.4	0.54	0.93	0.08	0.78	0.39	-0.13	0.1	0.81	0.55	0.79	-0.27	-0.42	0.07
Cost Of Revenue	0.4	0.63	-0.2	0.7	0.93	0.83	0.95	0.2	0.31	0.65	0.4		0.86	0.26	0.31	0.19	0.21	0.66	-0.2	0.03	-0.2	-0.01	0.01	-0.18	-0.32
Total Operating Expenses	0.69	0.85	0.2	0.93	0.98	0.98	0.97	0.3	0.37	0.89	0.54	0.86		0.31	0.1	0.25	0.17	0.42	0.01	0.05	0.06	0.04	-0.08	-0.05	0.03
Income Before Tax	0.19	0.35	0.36	0.26	0.37	0.4	0.3	0.94	1.0	0.28	0.93	0.26	0.31		0.06	0.76	0.48	-0.14	0.01	0.95	0.54	0.9	-0.1	-0.48	-0.1
Total Other Income Expense Net	0.02	0.19	0.03	-0.02	0.13	0.02	0.2	-0.26	0.08	-0.04	0.08	0.31	0.1	0.06		-0.01	-0.09	0.33	-0.44	0.06	-0.3	-0.25	-0.22	0.0	-0.04
Net Income	0.31	0.32	0.29	0.26	0.28	0.32	0.23	0.76	0.78	0.38	0.78	0.19	0.25	0.76	-0.01		0.1	-0.23	0.49	0.72	0.34	0.75	0.0	-0.22	0.16
Income Tax Expense	-0.02	0.16	-0.04	-0.02	0.23	0.23	0.19	0.51	0.45	-0.01	0.39	0.21	0.17	0.48	-0.09	0.1		0.36	-0.21	0.4	0.32	0.46	0.24	-0.79	-0.69
Minority Interest	-0.07	0.15	-0.53	0.32	0.52	0.41	0.54	-0.19	-0.13	0.14	-0.13	0.66	0.42	-0.14	0.33	-0.23	0.36		-0.42	-0.27	-0.48	-0.34	0.43	-0.22	-0.6
Discontinued Operations	0.3	0.14	0.41	0.03	-0.07	0.01	-0.08	0.15	0.01	0.2	0.1	-0.2	0.01	0.01	-0.44	0.49	-0.21	-0.42		-0.02	0.37	0.16	-0.03	0.06	0.31
Net Income From Continuing Ops	-0.05	0.08	0.32	0.02	0.11	0.14	0.04	0.89	0.94	0.01	0.81	0.03	0.05	0.95	0.06	0.72	0.4	-0.27	-0.02		0.5	0.92	-0.06	-0.43	-0.07
Tax Provision	0.34	0.34	0.7	0.09	-0.01	0.1	-0.05	0.57	0.51	0.16	0.55	-0.2	0.06	0.54	-0.3	0.34	0.32	-0.48	0.37	0.5		0.57	-0.5	-0.38	0.09
Interest Income	0.04	0.09	0.25	0.01	0.09	0.14	0.02	0.95	0.89	0.08	0.79	-0.01	0.04	0.9	-0.25	0.75	0.46	-0.34	0.16	0.92	0.57		-0.05	-0.47	-0.12
Extraordinary Items	-0.51	-0.44	-0.54	-0.09	0.02	0.02	-0.04	0.01	-0.13	-0.23	-0.27	0.01	-0.08	-0.1	-0.22	0.0	0.24	0.43	-0.03	-0.06	-0.5	-0.05		-0.02	-0.33
Net Interest Income	-0.04	-0.16	-0.02	0.11	-0.14	-0.11	-0.11	-0.47	-0.46	0.07	-0.42	-0.18	-0.05	-0.48	0.0	-0.22	-0.79	-0.22	0.06	-0.43	-0.38	-0.47	-0.02		0.55
Reconciled Depreciation	0.43	0.21	0.56	0.26	-0.11	0.01	-0.12	-0.11	-0.07	0.32	0.07	-0.32	0.03	-0.1	-0.04	0.16	-0.69	-0.6	0.31	-0.07	0.09	-0.12	-0.33	0.55

Click cells to compare fundamentals

Novartis Account Relationship Matchups

Novartis income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	850M	869M	811M	837M	855M	550.6M
Total Revenue	48.7B	49.9B	52.9B	51.8B	46.7B	46.2B
Gross Profit	34.3B	34.8B	37.0B	36.3B	34.2B	32.3B
Operating Income	9.1B	10.2B	26.9B	9.2B	9.8B	9.9B
Ebit	9.1B	10.2B	26.9B	9.2B	10.2B	10.5B
Research Development	9.4B	9.0B	9.5B	10.0B	11.4B	7.8B
Ebitda	15.6B	17.2B	33.1B	16.4B	18.5B	14.8B
Cost Of Revenue	14.4B	15.1B	15.9B	15.5B	12.5B	13.9B
Income Before Tax	8.9B	9.9B	26.1B	8.4B	9.1B	10.2B
Net Income	7.1B	8.1B	24.0B	7.0B	14.9B	9.7B
Income Tax Expense	1.8B	1.8B	2.1B	1.4B	551M	523.5M
Minority Interest	77M	68M	3M	2M	(4M)	(3.8M)
Tax Provision	1.8B	1.8B	2.1B	1.4B	1.4B	1.7B
Interest Income	36M	91M	14.6B	379M	627M	595.7M
Net Interest Income	(645M)	(947M)	(891M)	(633M)	(492M)	(516.6M)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Novartis AG ADR is a strong investment it is important to analyze Novartis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novartis' future performance. For an informed investment choice regarding Novartis Stock, refer to the following important reports:

How To Invest In Novartis

Details

Is Novartis Stock a good investment?

Details

What is Novartis' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Novartis Valuation and Novartis Correlation analysis.

You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Complementary Tools for Novartis Stock analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.

	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Stocks Directory Find actively traded stocks across global markets
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	CEOs Directory Screen CEOs from public companies around the world
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets

Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

4.987

Dividend Share

3.919

Earnings Share

4.1

Revenue Per Share

22.467

Quarterly Revenue Growth

0.074

The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Novartis Income Statement Research

Novartis income statement Correlations

Novartis Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Novartis income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Novartis Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Income Before Tax	+ 1.0	Ebit
Other Operating Expenses	+ 0.99	Total Revenue
Gross Profit	+ 0.98	Total Revenue
Total Operating Expenses	+ 0.98	Total Revenue
Total Operating Expenses	+ 0.98	Gross Profit
Total Operating Expenses	+ 0.97	Other Operating Expenses

Net Interest Income	- 0.79	Income Tax Expense
Reconciled Depreciation	- 0.69	Income Tax Expense
Reconciled Depreciation	- 0.6	Minority Interest
Extraordinary Items	- 0.54	Selling General Administrative
Minority Interest	- 0.53	Selling General Administrative
Extraordinary Items	- 0.51	Depreciation And Amortization